Although existing MALT1 protease inhibitors have been shown to effectively reduce ABC-DLBCL tumor growth in mouse xenograft models, these inhibitors only abrogate the protease arm of MALT1 action and do not inhibit MALT1 scaffolding function so that the mechanisms for direct IKK activation and induced IκB degradation remain unobstructed. Here, MALT1 is linked to diffuse large B-cell lymphoma.